Cremin, S,Menton, JF,Canier, L,Horgan, M,Fanning, LJ

2012

January

Human Vaccines & Immunotherapeutics

The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts

Validated

()

human papillomavirus cervical cancer HPV vaccines HPV genotyping NONVACCINE HPV TYPES AGED 16-26 YEARS PARTICLE VACCINE CANCER WOMEN INFECTION DISEASE IMPACT

8

916

920

The aim of this study was to determine the cervical genotype profile of females who presented to an STI Clinic with external genital warts (EGW); and to determine the potential vaccine coverage prior to the uptake of the HPV vaccines.Sixty-one cervical scrapings were taken from females aged 18-35 y who had external genital warts or a history of external genital warts. The resulting 50 samples that were positive for HPV-DNA were subjected to genotype identification. Forty-six of these samples had detectable genotypes by LIPA analysis and most (78%, 36/46) had multiple low risk (LR) and high risk (HR) genotypes on the cervix. Twenty-five of these samples (54%) had more than 1 HR genotype. Of the 36 patients who had any HR genotypes, 18 (50%) were identified to have the most oncogenic HPV genotypes, namely 16 and 18. Three of these samples had both 16 and 18 on the cervix.The presence of multiple HR genotypes on the majority of cervical samples from a self-referred population of females with EGW is presented. This study is of importance since persistent HR-HPV is the necessary risk factor in the development of precancerous and cancerous lesions of the cervix. Gardisil, the quadrivalent HPV vaccine would have been useful in the prevention of 28% (13/46) of these infections.

DOI 10.4161/hv.20122